Component
Cognition and daily function in Alzheimer disease trials
Cognition and daily function in Alzheimer disease trials. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
The main 250-mg scyllo-inositol versus placebo analysis found no significant benefit on cognition or daily-function coprimary outcomes.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/inositol-research/21917766.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "12c45a11b8cd0ee3075caa1f7572feae2130af237934a0be5f388322b64a1040", "start_char": 0, "end_char": 1479, "text_sha256": "12c45a11b8cd0ee3075caa1f7572feae2130af237934a0be5f388322b64a1040"}
- experimental_model
- Randomized dose-ranging phase 2 trial
- exposure
- Scyllo-inositol (ELND005) 250, 1000 or 2000 mg twice daily versus placebo for up to 78 weeks
- limitations
- Distinct stereoisomer from myo-inositol. Higher-dose arms stopped for safety imbalance; biomarker changes do not establish clinical benefit.
- nutrient_topic
- Inositol research collection; topical membership is not evidence of a direct dietary effect. · Inositol (stereoisomer family)
- organism
- Homo sapiens
- plain_language
- Changing the inositol form does not guarantee a neurological benefit.
- primary_references
- [ino-p21917766] A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. (2011). https://pubmed.ncbi.nlm.nih.gov/21917766/ DOI: 10.1212/wnl.0b013e3182309fa5
- tissue_or_cell_type
- 353 participants with mild-to-moderate Alzheimer disease
Inositol: synthesis, signaling, mineral interactions and conditional deficiency (2026-09-17) · lines 1471–1482
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized dose-ranging phase 2 trial · source_derived_draft · unverified_draft
### ino-scyllo-clinical The main 250-mg scyllo-inositol versus placebo analysis found no significant benefit on cognition or daily-function coprimary outcomes. Condition category: normal nutrient_topic: Inositol research collection; topical membership is not evidence of a direct dietary effect. plain_language: Changing the inositol form does not guarantee a neurological benefit. organism: Homo sapiens tissue_or_cell_type: 353 participants with mild-to-moderate Alzheimer disease experimental_model: Randomized dose-ranging phase 2 trial limitations: Distinct stereoisomer from myo-inositol. Higher-dose arms stopped for safety imbalance; biomarker changes do not establish clinical benefit. exposure: Scyllo-inositol (ELND005) 250, 1000 or 2000 mg twice daily versus placebo for up to 78 weeks evidence_span: {"source_cache": "artifacts/inositol-research/21917766.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "12c45a11b8cd0ee3075caa1f7572feae2130af237934a0be5f388322b64a1040", "start_char": 0, "end_char": 1479, "text_sha256": "12c45a11b8cd0ee3075caa1f7572feae2130af237934a0be5f388322b64a1040"} [ino-p21917766] A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. (2011). https://pubmed.ncbi.nlm.nih.gov/21917766/ DOI: 10.1212/wnl.0b013e3182309fa5
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.